Xi Niu Cai Jing·2025-06-18 10:17Group 1 - Qingda Environmental Protection expects revenue for the first half of the year to increase by 75.12% to 143.22%, with projected revenue between 900 million to 1.25 billion yuan [1] - Yifeng Pharmacy plans to use 17 million yuan of idle fundraising for entrusted wealth management, purchasing structured deposit products from China Merchants Bank with an expected annual yield of 1.00% or 1.75% [1] - Dongfang Bio has obtained medical device registration certificates for three products, enhancing its product range in the domestic infectious disease testing field [1][2] Group 2 - Zhenhua Heavy Industries plans to repurchase shares with a total amount between 50 million to 100 million yuan, with a maximum repurchase price of 6.93 yuan per share [2] - Leshan Electric Power announced the resignation of its deputy general manager due to job transfer [3] - Aorite passed the FDA's cGMP inspection, indicating compliance with quality standards [4] Group 3 - Xiaogoods City intends to establish two wholly-owned subsidiaries in Hong Kong with registered capital of 50 million and 10 million HKD respectively [5] - Boteng Co. announced that its subsidiary passed the EU QP audit, confirming compliance with international quality management standards [6] - Songcheng Performance received a warning letter from the Zhejiang Securities Regulatory Bureau due to significant profit adjustments from accounting errors [6] Group 4 - Xin Fengming's wholly-owned subsidiary plans to acquire a 36% stake in Zhejiang Jinlian Port for 70.08 million yuan [6] - Huqin Technology's subsidiary is participating in a private equity investment fund with a commitment of 25 million yuan [8] - Aobi Zhongguang expects a revenue increase of approximately 117.18% for the first five months, with projected revenue of 363 million yuan [10] Group 5 - Shanghai Pharmaceuticals plans to issue corporate bonds not exceeding 5 billion yuan [12] - Zhangjiagang Bank received approval for the appointment of three directors [14] - Hainan Pharmaceutical's Norfloxacin capsules passed the consistency evaluation for generic drugs [16] Group 6 - Fushun Special Steel appointed two new deputy general managers [18] - Zhongman Petroleum won the exploration and development rights for the Zerafa II natural gas block in Algeria [21] - Wolong Electric Drive is planning to list on the Hong Kong Stock Exchange to enhance its global strategy [23] Group 7 - Qizhong Technology plans to repurchase shares with a total amount between 75 million to 150 million yuan [25] - Saito Bio's subsidiary received the European CEP certificate for Dexamethasone raw materials [27] - Jiangsu Guoxin's expansion project for 2×100 MW units has been approved [29] Group 8 - Shiyuan Co. submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [29] - Xiamen Tungsten's sales of new energy materials reached approximately 47,600 tons in the first five months, a year-on-year increase of about 20.95% [30] - Haoyuan Pharmaceutical's subsidiary passed the EU QP audit, confirming compliance with EU GMP standards [31] Group 9 - Zhonggong International signed a contract for the second phase of a soda ash plant project in Kazakhstan worth 337 million USD [32] - Wide Special Materials proposed a share repurchase plan with a total amount between 200 million to 400 million yuan [34] - Zhongchao Holdings announced multiple subsidiaries won contracts totaling 1.061 billion yuan for power cable procurement [34] Group 10 - Huahai Qingke proposed a share repurchase plan with a total amount between 50 million to 100 million yuan [36] - Chip Microelectronics signed equipment purchase contracts totaling 146 million yuan [36] - Dongfang Bio's chairman proposed a share repurchase plan not exceeding 50 million yuan [38] Group 11 - Minova's subsidiary received a drug registration certificate for Sacubitril/Valsartan tablets [40] - Jinnuo Chemical reported no significant changes in methanol sales prices recently [40] - Guosheng Jin控 announced the public recruitment of a general manager following the merger with Guosheng Securities [41] Group 12 - Yunnan Baiyao's JZ-14 capsule received approval for clinical trials [43] - Jingpin Special Equipment proposed a share repurchase plan with a total amount between 8 million to 12 million yuan [46] - BGI Genomics' handheld ultrasound product received a medical device registration certificate [46]